Etanercept in graft-versus-host disease
暂无分享，去创建一个
[1] A. Reiff,et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.
[2] B. Beutler,et al. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. , 1999, Gastroenterology.
[3] K. Oshimi,et al. Differential Effects of Anti-Fas Ligand and Anti-Tumor Necrosis Factor α Antibodies on Acute Graft-Versus-Host Disease Pathologies , 1998 .
[4] A. Hess,et al. Graft-versus-host disease: new directions for a persistent problem. , 1994, Blood.
[5] C A Smith,et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.
[6] P. Vassalli,et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease , 1987, The Journal of experimental medicine.